MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
JHEP Reports · 2023-08 · 5 (8) · 100727
DOI: 10.1016/j.jhepr.2023.100727 ↗Kurz gefasst
Fachartikel in der Zeitschrift JHEP Reports, 2023-08. Verfasst von Luis Antonio Díaz und 59 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institute on Alcohol Abuse and Alcoholism.
Abstract (Originalsprache)
Background & Aims: Model for End-Stage Liver Disease (MELD) score better predicts mortality in alcohol-associated hepatitis (AH) but could underestimate severity in women and malnourished patients. Using a global cohort, we assessed the ability of the MELD 3.0 score to predict short-term mortality in AH.
Methods
This was a retrospective cohort study of patients admitted to hospital with AH from 2009 to 2019. The main outcome was all-cause 30-day mortality. We compared the AUC using DeLong's method and also performed a time-dependent AUC with competing risks analysis.
Results
A total of 2,124 patients were included from 28 centres from 10 countries on three continents (median age 47.2 ± 11.2 years, 29.9% women, 71.3% with underlying cirrhosis). The median MELD 3.0 score at admission was 25 (20-33), with an estimated survival of 73.7% at 30 days. The MELD 3.0 score had a better performance in predicting 30-day mortality (AUC:0.761, 95%CI:0.732-0.791) compared with MELD sodium (MELD-Na; AUC: 0.744, 95% CI: 0.713-0.775; p = 0.042) and Maddrey's discriminant function (mDF) (AUC: 0.724, 95% CI: 0.691-0.757; p = 0.013). However, MELD 3.0 did not perform better than traditional MELD (AUC: 0.753, 95% CI: 0.723-0.783; p = 0.300) and Age-Bilirubin-International Normalised Ratio-Creatinine (ABIC) (AUC:0.757, 95% CI: 0.727-0.788; p = 0.765). These results were consistent in competing-risk analysis, where MELD 3.0 (AUC: 0.757, 95% CI: 0.724-0.790) predicted better 30-day mortality compared with MELD-Na (AUC: 0.739, 95% CI: 0.708-0.770; p = 0.028) and mDF (AUC:0.717, 95% CI: 0.687-0.748; p = 0.042). The MELD 3.0 score was significantly better in predicting renal replacement therapy requirements during admission compared with the other scores (AUC: 0.844, 95% CI: 0.805-0.883).
Conclusions
MELD 3.0 demonstrated better performance compared with MELD-Na and mDF in predicting 30-day and 90-day mortality, and was the best predictor of renal replacement therapy requirements during admission for AH. However, further prospective studies are needed to validate its extensive use in AH. Impact and implications: Severe AH has high short-term mortality. The establishment of treatments and liver transplantation depends on mortality prediction. We evaluated the performance of the new MELD 3.0 score to predict short-term mortality in AH in a large global cohort. MELD 3.0 performed better in predicting 30- and 90-day mortality compared with MELD-Na and mDF, but was similar to MELD and ABIC scores. MELD 3.0 was the best predictor of renal replacement therapy requirements. Thus, further prospective studies are needed to support the wide use of MELD 3.0 in AH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Departamento de Ciencias de la Salud, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Servicio Medicina Interna, Hospital El Pino, Santiago, Chile.
- Departamento de Ciencias Médicas, Facultad de Medicina y Odontología, Universidad de Antofagasta, Antofagasta, Chile.
- Department of Anesthesia & Perioperative Medicine, Western University, London, ON, Canada.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
- Fondo Nacional de Desarrollo Científico y Tecnológico
- ANID
Zitieren
APA
Díaz, L. A., Fuentes-López, E., Ayares, G., Idalsoaga, F., Arnold, J., Valverde, M. A., Perez, D., Gómez, J., Escarate, R., Villalón, A., Ramírez, C. A., Hernandez-Tejero, M., Zhang, W., Qian, S., Simonetto, D. A., Ahn, J. C., Buryska, S., Dunn, W., Mehta, H., …, & Bataller, R. (2023). MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Reports, 5(8), 100727. https://doi.org/10.1016/j.jhepr.2023.100727
Vancouver
Díaz LA, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Valverde MA, et al. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Reports. 2023;5(8):100727. doi:10.1016/j.jhepr.2023.100727
BibTeX
@article{Daz2023,
author = {Díaz, Luis Antonio and Fuentes-López, Eduardo and Ayares, Gustavo and Idalsoaga, Francisco and Arnold, Jorge and Valverde, María Ayala and Perez, Diego and Gómez, Jaime and Escarate, Rodrigo and Villalón, Alejandro and Ramírez, Carolina A and Hernandez-Tejero, Maria and Zhang, Wei and Qian, Steve and Simonetto, Douglas A and Ahn, Joseph C and Buryska, Seth and Dunn, Winston and Mehta, Heer and Agrawal, Rohit and Cabezas, Joaquín and García-Carrera, Inés and Cuyàs, Berta and Poca, Maria and Soriano, German and Sarin, Shiv K and Maiwall, Rakhi and Jalal, Prasun K and Abdulsada, Saba and Higuera-de-la-Tijera, Fátima and Kulkarni, Anand V and Rao, P Nagaraja and Salazar, Patricia Guerra and Skladaný, Lubomir and Bystrianska, Natália and Clemente-Sanchez, Ana and Villaseca-Gómez, Clara and Haider, Tehseen and Chacko, Kristina R and Romero, Gustavo A and Pollarsky, Florencia D and Restrepo, Juan Carlos and Castro-Sanchez, Susana and Toro, Luis G and Yaquich, Pamela and Mendizabal, Manuel and Garrido, Maria Laura and Marciano, Sebastián and Dirchwolf, Melisa and Vargas, Victor and Jiménez, César and Louvet, Alexandre and García-Tsao, Guadalupe and Roblero, Juan Pablo and Abraldes, Juan G and Shah, Vijay H and Kamath, Patrick S and Arrese, Marco and Singal, Ashwani K and Bataller, Ramon},
title = {MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis},
journal = {JHEP Reports},
year = {2023},
volume = {5},
number = {8},
pages = {100727},
doi = {10.1016/j.jhepr.2023.100727}
}
EUVIMED